PDL BIOPHARMA, INC. 4
4 · PDL BIOPHARMA, INC. · Filed Jan 28, 2016
Insider Transaction Report
Form 4
Stone Christopher Lewis
VP and General Counsel
Transactions
- Award
Common stock
2016-01-26$3.22/sh+101,860$327,989→ 236,309 total
Footnotes (1)
- [F1]The restricted stock will vest, provided that the officer remains employed by the Company and certain performance goals are achieved,based upon the following schedule: 50% on December 2017; 16.66% on December 2018; 16.66% on December 2019; and 16.66% on December 2020.